Arcus, Infinity to evaluate two triple combination therapies in selected tumor types

This article was originally published here

Arcus Biosciences and Infinity Pharmaceuticals have entered into a clinical collaboration to evaluate two triple combination therapies in certain tumor types which typically show minimal response to checkpoint inhibition monotherapy.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply